There are currently 60 COVID-19 vaccines in clinical development, and 172 vaccines in pre-clinical development, according to the WHO. Here are the biggest developments from the last 10 days. 

AstraZeneca’s vaccine gets first authorization

On December 30, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorized emergency supply​ of 'COVID-19 Vaccine AstraZeneca' (AZD1222) for people 18 years and older. It marks the first authorization received by the Oxford University / AstraZeneca vaccine: with the company continuing to work towards authorization in other markets.

Today, 82-year-old Brian Pinker from Oxford became the first person​ (outside of clinical trials) to receive the vaccine.

Moderna publishes Phase 3 trial results

Moderna has published its Phase 3 results for mRNA-1273 in the New England Journal of Medicine,​ following the release of basic details from the primary efficacy analysis at the end of November.

The 100 μg two-dose regime of the Moderna COVID-19 vaccine was given 28 days apart. The primary endpoint of the 30,000-strong Phase 3 COVE study was based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This final analysis was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus 11 cases observed in the Moderna COVID-19 Vaccine group, corresponding to a 94.1% vaccine efficacy.

The vaccine was authorized for emergency use in the US​ on December 18, followed by Health Canada on December 23. Last week Moderna confirmed a 40 million dose supply agreement with the Government of the Republic of Korea; and an agreement with CDMO Recipharm to support formulation and fill-finish outside the US (which will be performed by Recipharm’s drug product manufacturing facility in France).

Source link